The efficacy of checkpoint inhibitor therapy illustrates that cancer immunotherapy, which aims to foster the host immune response against cancer to achieve durable anticancer responses, can be successfully implemented in a routine clinical practice. However, a substantial proportion of patients does not benefit from this treatment, underscoring the need to identify alternative strategies to defeat 
Introduction
Immunologists have long considered that the primary function of the immune system is to distinguish between self and non-self. However, the idea that the immune system only reacts to foreign organisms and is tolerant to self was difficult to reconcile with observations that individuals could feature antibodies to self-antigens, including DNA. In 1994, Polly Matzinger challenged the so-called Self-Nonself theory and proposed instead that the driving force that makes the immune system effective lies on its ability to recognize danger (1) . Among the immune cell types able to detect danger, dendritic cells (DCs) are of central importance because of their ability to capture, process, and present antigens to T cells (2) .The detection of danger by DCs relies on their expression of pattern recognition receptors (PRRs), which permit sensing, integration and transmission of danger signals to induce adaptive immunity. PRRs include membrane C-type lectins, Toll-like receptors (TLRs), cytoplasmic NOD-like receptors (NLRs) and DNA/RNA sensors (3, 4) . These receptors allow DCs to sense pathogensas well as endogenous danger signals released from dying cells such as DNA (5, 6) . These recognition mechanisms in DCs can be harnessed to generate more efficient cancer vaccines. For instance, immunogenicity of peptide-protein vaccines can be enhanced by the addition of adjuvants. These include agonists of various TLRs such as TLR3 (poly I:C), TLR4 (monophosphoryl lipid A; MPL), and TLR9 (CpG) (7) (8) (9) (10) (11) (12) .
The functional properties of DCs prompted their use as a tool in cancer immunotherapy with the aim of inducing anticancer immune responses. Initially, the use of non-targeted short peptides captured by DCs in vivo demonstrated that MHC class I-restricted antigen-specific CD8 + T cell immunity could be mounted in patients with metastatic disease (13) (14) (15) . The clinical successes wereyet limited, possibly because of the lack of CD4 + T cell help necessary for the generation of potent cytotoxic T lymphocytes(CTLs) and long-lived memory CD8 + T cells (16) (17) (18) . While the 4 clinical ineffectiveness of dendritic cell-based vaccinesis attributable to the immunosuppressive cancer microenvironment that curtails the induction of anticancer immune responses (19, 20) , the impressive successesof checkpoint inhibitor therapies, which result in 20-40% complete responses in some metastatic cancers, illustrate that cancer-induced immunosuppression can be pharmacologically overcome and anticancer immunity restored (21, 22) . This altogether suggests that a better knowledge of DC biology is required to design DC vaccines able to reverse tumor-induced immunosuppression and elicit long-term anticancer responses.
DNA is a potent immune stimulatory molecule widely used as vaccine adjuvant to drive immunity (4, 23) .Initially, TLR9 was identified as the sensor for DNA. TLR9 recognizes pathogen derived CpG DNA to trigger innate immune signaling predominantly in plasmacytoid dendritic cells (pDCs) (24) . TLR9 was also shown to be responsible for the detection of self-DNA, leading to autoimmunity (25, 26) . While TLR9 was promoting immune signaling following its interaction with DNA in endosomes, the mechanisms responsible for the detection of cytosolic DNA were unclear until the characterization of STING (Stimulator of Interferon Genes).
In 2008, STING was described as a transmembrane component of the endoplasmic reticulum (ER) essential for the production of type I IFN in fibroblasts, macrophages and dendritic cells (DCs) in response to cytoplasmic double-stranded DNA (dsDNA) as well as select DNA viruses and intracellular bacteria (27, 28) . Interestingly, STING does not share homology with any known immunosensor and seems to represent a novel category of proteins involved in immune signaling in the context of cytosolic DNA presence, with an ability to link the majority of DNA sensors to immune signaling (29, 30) . The detection of DNA indeed relies on a variety of cytoplasmic DNA sensors, including the cyclic GMP-AMP synthase (cGAS) (31) . The discovery of cGAS in 2013
actually represented a significant advance in our understanding of the signaling mechanisms underpinning innate DNA sensing. After binding to cytosolic DNA species from viruses, bacteria, or self -DNA from the nucleus or mitochondria, cGAS catalyzes the production of a type of cyclic dinucleotide (CDN) named cGAMP (cyclic GMP-AMP) (32, 33) . Following binding to CDNs, STING activation leads to the phosphorylation of interferon regulatory factor 3 (IRF3) and nuclear factor-κB (NFκB) and the subsequent induction of cytokines and proteins, such as the type I interferons (IFN) that exert anti-pathogen activities (28, 34) . STING was proposed to be activated by other cytoplasmic DNA sensors, including DAI, DHX9, DHX36, IFI204 (IFI16), DDX41, DXX60, Pol III, LRRFIP1, DNA-PK, cGAS and the DNA repair protein Mre11 (35) ,that bind DNA directly and act upstream of STING to induce type I IFNs (30) . This together defines STING as an adaptor protein that is essential for immune signaling following pathogen DNA detection by cytoplasmic DNA sensors (reviewed in (36) ). Recent reports have also indicated that potent activators of the STING pathway may also include self-DNA that has leaked from the nucleus of the host cell, perhaps following cell division or as a consequence of DNA damage (37) . STING is thus central to the induction of immune responses following DNA detection.
In this review, we discuss recent findings illustrating the links between STING signaling in immune and cancer cells and cancer progression. We also describe emerging strategies that exploit the STING signaling pathway to enhance anticancer immune responses. We eventually highlight the relevance of modulating the STING pathway for cancer immunotherapy. 
STING in spontaneous anti-cancer immunity
While the findings discussed above suggest that STING-driven chronic inflammation leads to cancer, STING-dependent DNA detection was also found to trigger anticancer immunity (29, 31) .
Importantly, activation of the STING pathway was correlated to the induction of a spontaneous antitumor T cell response involving the expression of Type I interferon (IFN) genes (29, 31 (Figure 2A ). STING protein is predominantly expressed in macrophages, T cells, DCs endothelial cells and select fibroblasts and epithelial cells (27, 28, (45) (46) (47) .
However, in the tumor microenvironment, the main sources of IFN-β are DCs and endothelial cells (48, 49) . One hypothesis to account for these observations is that CD8α 
STING in intestinal wound repair and therapy-induced anti-cancer immunity
The anticancer effects of STING activation were also demonstrated in a model of colitisassociated carcinogenesis (CAC). CAC can be experimentally induced by carcinogens and inflammatory agents such as azoxymethane (AOM) and dextran sulfate sodium (DSS) (52, 55) . Recent studies have shown that the STING pathway is also implicated in radiation-induced antitumor T cell responses (50) . Antitumor effects of radiation were previously shown to be dependent on type I IFN signaling (60) . Moreover, radiation induces cell stress and causes excess DNA breaks, indicating that nucleic acid sensing could account for the induction of type I IFNs upon radiation.
Accordingly, the induction of IFN-β in tumors was reduced in the absence of STING in the host after radiation. In line with the immunogenicity of IFNs, the anticancer efficacy of radiation therapy was impaired in STING-deficient mice compared to controls, suggesting that STING-dependent cytosolic DNA sensing is critical for the therapeutic effect of radiation in vivo (50) .STING was further shown to be essential for tumor-infiltrating DCs type I IFN production after radiation. (66) . These studies altogether demonstrate that STING expression by tumor cells can shape their immunogenicity and make a decisive contribution to cancer cell immunosurveillance ( Figure 3D) . 12 
STING in cancer immunotherapy

6.1.Pioneering studies for pharmacological use of STING agonists in immunotherapy
The first pharmacological STING agonist was initially used as an anticancer drug long before the discoveryof STING. Flavone acetic acid (FAA) has potent antitumor activity against murine colon tumors ( Table 1 )(67). The further characterization of FAA as vascular disrupting agent led to testing its clinical potential. However, FAA failed in a phase I clinical trial and showed no activity in rat tumor models implying possible species specificity issues (68) . To obtain compounds able to induce tumor hemorrhagic necrosis, the molecular structure of FAA was modified giving rise to 5,6-dimethyllxanthenone-4-acetic acid (DMXAA), which not only showed activity against a rat mammary carcinoma but also featured IFNs and TNF-dependent anticancer functions in different mouse models (69, 70) . Unfortunately Phase III trials in non-small-cell lung cancer (NSCLC) patients failed to confirm the anti-tumor effect of DMXAA in humans (71) . Further molecular characterization revealed that the mechanism underlying DMXAA-induced type I IFNs and TNF-α secretion and anticancer activity wasSTING dependent (72 
Cyclic dinucleotides (CDNs) STING agonists as potent anti-cancer agents in mice
As previously discussed, CDNs are second messengers able to activate the STING pathway, leading to type I IFNs and pro-inflammatory cytokine expression (76) . In mice, cyclic diguanylate monophosphate (c-di-GMP) showed anti-tumor effects in the 4T1 metastatic breast cancer model when daily injected at low doses after immunization with an attenuated Listeria monocytogenes (LM)-based vaccine ( Table 1 and Figure 4A )(77). These observations were confirmed in the GL261 glioma murine modeland in the B16 melanoma bearing mice treated with c-di-GMP associated with the TRIVAX vaccine, a mix of synthetic CD8 T cell epitopes ( Table 1 and Figure   4D ).Woo and colleagues also tested the contribution of STING signaling in context of combined 14 treatment with checkpoint inhibitors and found that the therapeutic effect of CTLA-4 and anti-PD-L1 mAbs was lost in STING-deficient mice (44) . Their results suggest that the host STING pathway plays a critical role in the therapeutic efficacy of cancer immunotherapies and provide impetus to deliberately activate STING using STING agonists for treating cancer. Thus, manipulation of STING signaling can be successfully integrated in the context of combination therapies( Table 1) .
In addition to its established role as a signaling adaptor in the response to cytosolic DNA, STING was proposed to function as a direct sensor able to directly bind different DNA species or CDNs (76, 83) . Biotin pull-down assays using in vitro transcribed STING and different biotinylated DNA species showed that STING directly binds ssDNA and dsDNA without a requirement for accessory molecules (83) . Moreover, using radiolabeled c-di-GMP 32 binding assays, Burdette and colleagues shown that STING can also directly and specifically binds CDNs(76) in contrast to a study showing that c-di-GMP was detected by DDX41 (84) . To unveil the underlying mechanism,
Parvatiyar and colleagues performed binding assays to determine the affinities of c-di-GMP for DDX41 and for STING in parallel. Physiologically, binding of c-di-GMP with endogenous DDX41 turned out to be greater than the association between c-di-GMP and endogenous STING.
Accordingly, c-di-GMP bound to purified recombinant DDX41 with stronger affinity than purified recombinant STING in pulldown binding assays. These findings thus suggest that even though STING can directly bind c-di-GMP, DDX41 is the major sensor of c-di-GMP, operating upstream of STING to facilitate downstream signaling and type I IFN activation (84) . In line with this work, Zhang and colleagues found that c-di-GMP bound to STING with a Kd of 1.21 μM(85).
Interestingly, both natural cGAMP and synthetic 2′3′-cGAMP bound to STING with a high affinity (85) . Indeed, the Kd of 2′3′-cGAMP was nearly 300 fold lower than those of c-di-GMP, 3′2′-cGAMP and 3′3′-cGAMP, and around 75 fold lower than that of 2′2′-cGAMP. In addition, unlike the binding of c-di-GMP, which is an exothermic process, the binding of natural and 2′3′-cGAMP to STING was endothermic, suggesting that the energy may be used for STING conformational change (85) . The authors further showed that 2′3′-cGAMP and other cGAMP isomers are much more potent than c-di-GMP in inducing IFNβ in cells (85) . Overall, these resultsillustrate the potential to design cGAMP isomers with a potentially enhanced ability to trigger type I IFN secretion, thereby resulting in more potent anticancer immune responses.
STING agonists for cancer treatment in humans
In 2014, Li discovered an ecto-nucleotide pyrophosphatase/phosphodiesterase enzyme named ENPP1 (86) . This enzyme is a 2'3'cGAMP hydrolizing protein, giving rise to a hydrolysis-resistant bisphosphothioate analog of 2′3′-cGAMP named 2′3′-cG 
